- Home
- CPRX
as 07-26-2024 4:00pm EST
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 1.8B | IPO Year: | 2006 |
| Target Price: | $27.80 | AVG Volume (30 days): | 798.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.54 | EPS Growth: | -39.33 |
| 52 Week Low/High: | $11.55 - $17.99 | Next Earning Date: | 08-07-2024 |
| Revenue: | $411,347,000 | Revenue Growth: | 60.38% |
| Revenue Growth (this year): | 18.21% | Revenue Growth (next year): | 17.63% |
Stock Insider Trading Activity of Catalyst Pharmaceuticals Inc. (CPRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Del Carmen Jeffrey | CPRX | Chief Commercial Officer | Jun 7 '24 | Sell | $16.07 | 7,541 | $121,183.87 | 18,427 | SEC Form 4 |
| INGENITO GARY | CPRX | Chief Med. & Reg. Officer | Jun 5 '24 | Sell | $16.16 | 80,000 | $1,292,800.00 | 51,391 | SEC Form 4 |
| Daly Richard J | CPRX | President and CEO | Jun 4 '24 | Sell | $15.98 | 17,323 | $276,734.93 | 234,824 | SEC Form 4 |
| Harper Molly | CPRX | Director | Jun 3 '24 | Sell | $16.30 | 5,333 | $86,949.23 | 0 | SEC Form 4 |
| Tierney David S | CPRX | Director | Apr 8 '24 | Sell | $15.68 | 25,000 | $392,000.00 | 348,874 | SEC Form 4 |
| Elsbernd Brian | CPRX | Chief Compliance/Legal Officer | Mar 27 '24 | Sell | $16.44 | 25,000 | $411,000.00 | 124,433 | SEC Form 4 |
| Harper Molly | CPRX | Director | Dec 15 '23 | Sell | $14.43 | 4,000 | $57,720.00 | 0 | SEC Form 4 |
| Harper Molly | CPRX | Director | Dec 15 '23 | Sell | $14.37 | 10,000 | $143,700.00 | 0 | SEC Form 4 |
| Tierney David S | CPRX | Director | Dec 12 '23 | Sell | $13.33 | 50,000 | $666,250.00 | 333,541 | SEC Form 4 |
| GRANDE ALICIA | CPRX | VP, Treasurer and CFO | Dec 8 '23 | Sell | $14.25 | 20,000 | $285,000.00 | 70,557 | SEC Form 4 |
| GRANDE ALICIA | CPRX | VP, Treasurer and CFO | Dec 8 '23 | Sell | $14.30 | 20,000 | $286,000.00 | 50,557 | SEC Form 4 |
| GRANDE ALICIA | CPRX | VP, Treasurer and CFO | Dec 8 '23 | Sell | $13.74 | 30,000 | $412,200.00 | 80,557 | SEC Form 4 |
| GRANDE ALICIA | CPRX | VP, Treasurer and CFO | Dec 8 '23 | Sell | $13.79 | 30,000 | $413,580.00 | 50,557 | SEC Form 4 |
| INGENITO GARY | CPRX | Chief Med. & Reg. Officer | Dec 6 '23 | Sell | $14.02 | 50,000 | $701,000.00 | 38,367 | SEC Form 4 |
| Miller Steve | CPRX | Chief Op. & Scientific Officer | Dec 5 '23 | Sell | $14.24 | 40,000 | $569,600.00 | 647,457 | SEC Form 4 |
Latest Catalyst Pharmaceuticals Inc. News
CPRX Breaking Stock News: Dive into CPRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
Argus Research
3 days ago
CPRX: What does Argus have to say about CPRX?
GlobeNewswire
4 days ago
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
Argus Research
10 days ago
CPRX: Raising target price to $18.00
Argus Research
17 days ago
CPRX: Lowering target price to $16.00
GuruFocus.com
a month ago
A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
Energy Global
a month ago
ANDRITZ to equip new Silvan hydropower plant in Türkiye
USA TODAY
a month ago
Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
Compare CPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CPRX Catalyst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.